

2771-515-CIP

RECEIVED
CENTRAL FAX CENTER

OCT 05 2006

REMARKS

Claims 1, 3-11 and 13-25 and new claims 26-40 are pending. Claims 2 and 12 have been cancelled without prejudice. Claims 16-25 have been previously withdrawn. Various claims have been amended for reciting proper antecedent basis. New claims 26-40 are directed to certain embodiments of the invention. No new matter (35 USC § 132) has been introduced.

Objection to Claim 5

Claim 5 is objected to and otherwise indicated to be allowable. In response, Applicants have amended claim 5 into independent form.

In view of the foregoing amendment of claim 5 into independent form, Applicants respectfully request allowance of claim 5 as it now stands.

Rejections Under 35 USC § 102(b) and 35 USC § 103(a)

Claims 1-4 and 6-15 are rejected under 35 USC § 102(b) as being anticipated by or, in the alternative, obvious under 35 USC § 103(a) over Blohm et al (US Pat No. 5,281,686; hereinafter "Blohm") for the reasons noted in pages 2-3 of the final Office Action.

Since Applicants have already cancelled claims 2 and 12, Applicants remarks below are directed to the rejection of 1, 3-4, 6-11 and 13-15 because the rejection of cancelled claims 2 and 12 is now moot. In response to the above-noted rejections over Blohm, Applicants have amended claim 1 (and therefore claims ultimately depending therefrom including claims 3-4, 6-11 and 13-15) to further recite the inclusion of a free radical inhibitor.

Additionally, in view of the cancellation of claims 2 and 12, claims 8 and 13-15 have been amended to depend from claim 6 instead of from cancelled claims 2 or 12. Because the Blohm patent does not disclose inclusion of a free radical inhibitor provided to stop free radical polymerization, claims 1, 3-4, 6-11, and 13-15 are not anticipated by nor rendered obvious by the Blohm reference.

Accordingly, Applicants respectfully request reconsideration and withdrawal of the aforementioned rejections of claims 1, 3-4, 6-11 and 13-15 over Blohm under 35 USC § 102(b) or 35 USC § 103(a).

New Claims 26-40

Note that new claims 26-40 do not encompass the combination of OMCTS together with bis(trimethylsiloxy)methylsilane. Also, the various features recited in claims 26-40 render these new claims patentable over Blohm. Accordingly, these new claims are also patentable over the Blohm patent.

